
|Articles|October 1, 2002
Vaccine could boost survival for node-negative melanoma
Ann Arbor, Mich. - An allogeneic melanoma vaccine - Melacine, made by Corixa Corp. - might provide a survival benefit in node-negative melanoma patients expressing specific HLA class I antigens, according to recent reports.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
5











